Sign up to save your podcasts
Or
Share "Almost Deported" CEO Leads Market
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
"Almost Deported" CEO Leads Market
“Because of the opioid epidemic I expect we can develop that market to $1 Billion a year because our products provide great pain relief without side effects.”
Thomas Sandgaard, Chairman and CEO, Zynex Medical
Zynex’s main product line treats pain with FDA-approved electric stimulation that reduces the need for opioids in the marketplace. Direct and understated, Thomas Sandgaard doesn’t seem at all impressed with his success. His story of starting with $2,000 twenty-four years ago, and building that into a public company valued at half a billion is pretty impressive. We discuss that, as well as Thomas’s transition from full-time CEO to a life that includes philanthropy, a UK football club, and a return to his rock-and-roll guitar roots.
View all episodes
By Dave Tabor, PROCO360
5
3131 ratings
“Because of the opioid epidemic I expect we can develop that market to $1 Billion a year because our products provide great pain relief without side effects.”
Thomas Sandgaard, Chairman and CEO, Zynex Medical
Zynex’s main product line treats pain with FDA-approved electric stimulation that reduces the need for opioids in the marketplace. Direct and understated, Thomas Sandgaard doesn’t seem at all impressed with his success. His story of starting with $2,000 twenty-four years ago, and building that into a public company valued at half a billion is pretty impressive. We discuss that, as well as Thomas’s transition from full-time CEO to a life that includes philanthropy, a UK football club, and a return to his rock-and-roll guitar roots.